Why TG Therapeutics, Inc. Stock Was Whipsawed

TG Therapeutics delivers impressive preliminary phase 1 clinical data for its investigational combo designed to treat blood cancers. Find out why investors are giving this data release a mixed review.

Jul 22, 2014 at 1:22PM

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of TG Therapeutics (NASDAQ:TGTX), a clinical-stage biopharmaceutical company primarily focused on developing novel therapies to treat cancer, briefly spiked higher this morning by as much as 11% after announcing preliminary clinical results from its phase 1 study involving TG-1101 and TGR-1202 for patients with previously treated chronic lymphocytic leukemia, or CLL, and aggressive lymphomas. Shares have since given up all of their gains and dipped as much as 9% since its early morning pop.

So what: According to TG Therapeutics' press release the combination of TG-1101 and TGR-1202 demonstrated "compelling early activity" in treating CLL and aggressive lymphomas in preliminary phase 1 results.

Per its data, four of the five evaluable CLL and small lymphocytic leukemia, or SLL, patients achieved a partial response at their first assessment, while the fifth patient demonstrated stable disease with 44% nodal reduction noted. However, all five patients exhibited an absolute lymphocyte count (ALC) reduction equal to or greater than 50% by the first assessment with one of the five patients achieving a 80% reduction or greater in ALC (essentially a complete normalization) by the first assessment. The combo also appeared to be safe and well-tolerated.

In the second portion of its phase 1 study which combined TG-1101 and TGR-1202 to combat non-Hodgkin's lymphoma or patients with Richter's syndrome, out of the 10 evaluable patients nine demonstrated signs of stable disease or better. Specifically, TG Therapeutics notes that one patient in the single-agent phase 1 study receiving TGR-1202 with GCB-subtype diffuse large B-cell lymphoma had a greater than 40% reduction in tumor mass which remained stable for more than six months.

Now what: On one hand we have extremely positive early stage data that clearly got investors excited this morning. This follows other key recent news, such as its global licensing agreement of Ligand Pharmaceuticals' IRAK4 inhibitor research program, and its stellar combo results last month involving TG-1101 when combined with Pharmacyclics' Imbruvica. Then again, we have to remember that we're looking at a very small evaluable pool of patients, and a lot can change when a drug moves into a larger scale study. TG Therapeutics has already seen a huge run higher and has basically doubled over the past two months, so much of that optimism may already be baked into its shares. Personally, I find the company's early work extremely intriguing and I've added it to my Watchlist, although I'd like to see more encompassing data before considering taking the plunge.

TG Therapeutics may offer plenty of potential, but it'll probably wind up being left in the dust by this revolutionary new product! 
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers